Clinical trials
Grade III Glioma clinical trials
Below are recruiting grade iii glioma clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06632236RecruitingPhase 1
Amivantamab for advanced brain tumors
This trial tests a new drug called amivantamab for people with advanced brain tumors, including glioblastoma. It aims to see if the drug can shrink or slow tumor growth.
CambridgeAges 16 years+ - NCT04299191RecruitingPhase 1/Phase 2
LAM561 for children with advanced brain or solid tumors
This Phase 1/2 study tests a medicine called LAM561 in children whose cancer is advanced and not responding to standard treatment. The goal is to see if the drug is safe and can shrink or control tumors in this setting.
Little Rock, ArkansasAges Up to 18 years - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT07179328RecruitingPhase 1
Focused ultrasound for glioblastoma during standard chemo
This trial tests whether focused ultrasound can safely open the blood-brain barrier to help your chemotherapy work better. It is for people with glioblastoma who have already completed standard surgery and chemo-radiation and are now on maintenance chemo.
Toronto, OntarioAges 18–85 - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05768919RecruitingPhase 1/Phase 2
Liposomal curcumin with radiation and temozolomide for new brain cancer
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06126744RecruitingPhase 1
Study of a virus therapy for recurrent brain cancer
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
New York, New YorkAges 18 years+ - NCT06528691RecruitingPhase 2
Entrectinib for young children with NTRK/ROS1 brain tumors
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
Memphis, TennesseeAges Up to 3 years - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT06999148Enrolling by invitationPhase 2
Testing sonodynamic therapy with radiation and chemo for brainstem glioma
This trial tests whether adding sonodynamic therapy (a treatment that uses sound waves to activate a drug) before standard radiation and chemotherapy can help people with a type of brainstem glioma called DIPG. The goal is to see if this combination improves survival.
Zhengzhou, UndefinedAges Up to 75 years - NCT06160492RecruitingPhase 3
Testing a Glowing Dye to Improve Brain Tumor Removal
This trial compares two surgical techniques for removing malignant brain tumors: one using a special dye (5-ALA) that makes tumor cells glow under a blue light, versus the standard white light surgery. The goal is to see if the dye-guided approach helps surgeons remove more of the tumor safely.
Guangzhou, GuangdongAges 18–70 - NCT03643549RecruitingPhase 1/Phase 2
Combination treatment for recurring brain cancer
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
BergenAges 18 years+ - NCT06703255RecruitingPhase 1/Phase 2
Testing HX301 for advanced high-grade glioma
This trial tests an experimental drug called HX301 for people with high-grade gliomas (fast-growing brain tumors). It is for patients whose tumor has come back after temozolomide chemo, or for those with newly diagnosed glioblastoma that has been surgically removed. The study aims to see if HX301 can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07648823RecruitingEarly Phase 1
New radioactive treatment for recurrent brain tumors
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
Beijing, Beijing MunicipalityAges 18–80 - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+
Hear when a new Grade III Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for grade iii glioma?
- Yes. Clin2 currently lists 63 recruiting grade iii glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a grade iii glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a grade iii glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.